Morano Susan E purchased $100K of BSX

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Boston Scientific (BSX) appointed Joseph M. Fitzgerald as COO, effective January 1, 2027, and restructured operations into three segments. The company is valued at $42.19, with a GF Value™ of $107.35, indicating a 60.7% undervaluation. BSX has a GF Score™ of 79, reflecting strong financial health and growth prospects, despite net insider selling and mixed guru activity.

Boston Scientific appointed Joseph Fitzgerald as its new Chief Operating Officer. Separately, Citigroup lowered its price target on the company to $48 from $50, maintaining a neutral rating. The stock closed at $42.19, down 0.50%.

Barclays initiated coverage of Boston Scientific (BSX) with an Underweight rating and $165 price target. The firm sees opportunities in high-quality medical device stocks but expects sector fundamentals to stabilize in 2027. Barclays' top picks include Edwards Lifesciences, Stryker, Beta Bionics, DexCom, and LivaNova.

FDA cleared Boston Scientific's SpaceOAR Flex Hydrogel, a rectal spacer for prostate cancer radiation therapy. The company claims it offers simpler setup and flexible delivery. Interim trial data showed 92.4% of patients had a 25% reduction in rectal radiation dose. Boston Scientific funded the study.

Boston Scientific reported mixed Q2 2026 results, with Endoscopy sales up 7% YoY and Neuromodulation up 12%, but Urology underperforming. The company received FDA clearance for RIVOS and plans key launches to boost Urology growth. BSX shares fell 30.2% over six months, trading at a forward P/S ratio of 2.89. Medtronic and Teleflex also reported recent developments.